1205-58-9

Basic information

• Product Name: 4-[(ACETYLAMINO)METHYL]BENZOIC ACID
• Synonyms: p-Toluicacid, a-acetamido- (6CI,7CI,8CI);4-[(Acetylamino)methyl]benzoic acid; N-Acetyl-4-aminomethylbenzoic acid; N-Acetyl-p-aminomethylbenzoicacid; p-(Acetamidomethyl)benzoic acid
• CAS NO: 1205-58-9
• Molecular Formula: C₁₀H₁₁NO₃
• Molecular Weight: 193.2
• Mol File: 1205-58-9.mol

Chemical Properties

• Melting Point: 194-196 °C
• Boiling Point: 469.5°Cat760mmHg
• Flash Point: 237.7°C
• Appearance: /
• Density: 1.228g/cm³
• Vapor Pressure: 1.17E-08mmHg at 25°C
• Storage Temp.: 2-8°C
• PKA: 4.25±0.10(Predicted)
• CAS DataBase Reference: 4-[(ACETYLAMINO)METHYL]BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(ACETYLAMINO)METHYL]BENZOIC ACID(1205-58-9)
• EPA Substance Registry System: 4-[(ACETYLAMINO)METHYL]BENZOIC ACID(1205-58-9)

Safety Data

• Hazardous Substances Data: 1205-58-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-[(Acetylamino)methyl]benzoic acid is used as an active ingredient in over-the-counter pain relievers and fever reducers for its analgesic and antipyretic properties, helping to alleviate discomfort and reduce fever in consumers.
Used in Medicinal Chemistry:
As a versatile intermediate, 4-[(Acetylamino)methyl]benzoic acid is used in the synthesis of a wide range of pharmaceuticals, contributing to the development of new medications with diverse therapeutic applications.
Used in Anti-inflammatory Drug Development:
4-[(Acetylamino)methyl]benzoic acid is utilized in the production of anti-inflammatory drugs, targeting specific biological pathways to reduce inflammation and provide relief from various inflammatory conditions.
Used in Chemical Industry:
4-[(ACETYLAMINO)METHYL]BENZOIC ACID serves as a building block in the chemical industry for the creation of new molecules with therapeutic properties, expanding the scope of available treatments and advancing pharmaceutical research.

InChI:InChI=1/C10H17NO3/c1-7(12)11-6-8-2-4-9(5-3-8)10(13)14/h8-9H,2-6H2,1H3,(H,11,12)(H,13,14)/p-1

Upstream product

• 56-91-7 p-aminomethylbenzoic acid 
• 64-19-7 acetic acid 
• 108-24-7 acetic anhydride 

Downstream Products

• 20686-40-2 4-(acetylamino-methyl)-benzoic acid methyl ester 
• 136869-07-3 N-acetyl(4-hydroxymethyl)benzylamine 
• 223512-41-2 N-(4-chloromethyl-benzyl)-acetamide 
• 223512-42-3 N-(4-((4-phenylpiperazin-1-yl)methyl)phenylmethyl)acetamide 
• 223511-24-8 N-(4-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenylmethyl)acetamide 

Relevant articles and documents

Harnessing the anti-nociceptive potential of nk2 and nk3 ligands in the design of new multifunctional μ/δ-opioid agonist–neurokinin antagonist peptidomimetics

Opioid agonists are well-established analgesics, widely prescribed for acute but also chronic pain. However, their efficiency comes with the price of drastically impacting side effects that are inherently linked to their prolonged use. To answer these liabilities, designed multiple ligands (DMLs) offer a promising strategy by co-targeting opioid and non-opioid signaling pathways involved in nociception. Despite being intimately linked to the Substance P (SP)/neurokinin 1 (NK1) system, which is broadly examined for pain treatment, the neurokinin receptors NK2 and NK3 have so far been neglected in such DMLs. Herein, a series of newly designed opioid agonist-NK2 or-NK3 antagonists is reported. A selection of reported peptidic, pseudo-peptidic, and non-peptide neurokinin NK2 and NK3 ligands were covalently linked to the peptidic μ-opioid selective pharma-cophore Dmt-DALDA (H-Dmt-D-Arg-Phe-Lys-NH2 ) and the dual μ/δ opioid agonist H-Dmt-D-Arg-Aba-βAla-NH2 (KGOP01). Opioid binding assays unequivocally demonstrated that only hybrids SBL-OPNK-5, SBL-OPNK-7 and SBL-OPNK-9, bearing the KGOP01 scaffold, conserved nanomo-lar range μ-opioid receptor (MOR) affinity, and slightly reduced affinity for the δ-opioid receptor (DOR). Moreover, NK binding experiments proved that compounds SBL-OPNK-5, SBL-OPNK-7, and SBL-OPNK-9 exhibited (sub)nanomolar binding affinity for NK2 and NK3, opening promising opportunities for the design of next-generation opioid hybrids.

KINASE INHIBITORS

The invention provides the use of a compound or a composition comprising said compound for inhibiting the activity of at least one kinase, other than ROCK kinase, in vitro or in vivo, pharmaceutical and/or veterinary compositions comprising such compounds, medical and veterinary uses of such compounds and the compounds themselves.

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.

Imidazole derivatives

The present invention relates to the imidazole derivative of the following formula (I) wherein R1 is hydrogen, optionally substituted alkyl and the like, R2 is hydrogen, optionally substituted alkyl and the like, R3is optionally substituted heteroaryl, R4 is optionally substituted cycloalkyl, optionally substituted phenyl and the like, provided that when R1 is hydrogen, and R2 and R4 are the same or different and each is phenyl or phenyl substituted by halogen atom, lower alkyl or lower alkoxy, R3 is benzothiazolyl or thiazolyl substituted by phenyl, the imidazole derivative of the following formula (XII) wherein R6 is optionally substituted phenyl or optionally substituted heteroaryl and R7 is substituted phenyl, and pharmaceutically acceptable salts thereof. The compounds of the formulas (I) and (XII) and pharmaceutically acceptable salts thereof of the present invention inhibit IL-4 and IL-5 production by Th2 cells and are effective for the prophylaxis and treatment of allergic diseases such as atopic dermatitis, bronchial asthma, allergic rhinitis and the like.

Novel phenylpiperazine derivatives as dual cytokine regulators with TNF-α suppressing and IL-10 augmenting activity

Phenylpiperazine derivatives were synthesized as dual cytokine regulators with TNF-α suppressing and IL-10 augmenting activity. Lead optimization led to compound 5k having the potent regulatory activity and demonstrating remarkable protective effects against the lethal challenge of LPS in mice, suggesting that 5k would be a promising drug candidate for the treatment of TNF-α associated diseases including septic shock. (C) 2000 Elsevier Science Ltd. All rights reserved.

Substituted benzene derivatives useful as neuraminidase inhibitors

A compound of the Formula (I): STR1 or pharmaceutically-suitable salts or prodrug forms thereof, wherein: n is 0-1; m is 0; p is 0-1; R1 is --CO2 H; R2 is selected from the group consisting of H, --OH, and --NH2 ; R3 is H; R4 is --C(O)NHR8 ; R5 is --NHC(R6)NH2 R6 is selected from the group consisting of =NH, =NOH, =NCN, =O, and =S; and R8 is selected from the group consisting of C1 -C4 linear or branched alkyl substituted with 0-3 halogens on each carbon.

Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design

A series of 94 benzoic acid derivatives was synthesized and tested for its ability to inhibit influenza neuraminidase. The enzyme-inhibitor complex structure was determined by X-ray crystallographic analysis for compounds which inhibited the enzyme. The most potent compound tested in vitro, 5 (4- (acetylamino)-3-guanidinobenzoic acid), had an IC50 = 2.5 x 10-6 M against N9 neuraminidase. Compound 5 was oriented in the active site of the neuraminidase in a manner that was not predicted from the reported active site binding of GANA (4) with neuraminidase. In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally.

Aminoalkylphenyl compounds

Aminoalkylphenyl derivatives of formula I STR1 wherein alk, R1 -R6, X and Y are as defined in the description, and salts thereof, exhibit properties inhibiting the biosynthesis of interleukin-1 (IL-1) and analgesic properties and can